TransCode Therapeutics Inc. RNAZ
1.69
0.04
2.42%
as of 25 Sep
- Market cap
- $27.9M
- P/E
- 0.0×
Follow RNAZ
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
1.60 | 6.29 | 3.11 | 1.97 |
Net Debt/EBITDA |
0.62 | 1.11 | 0.72 | 1.24 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.84 | 0.54 | 0.26 | 0.79 | |
Capex/Depreciation |
0.00 | (0.15) | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.86 | 0.89 | 0.93 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | 0.00% | |
Free Cash Flow per Share |
(4.90) | (11.81) | (5.43) | (5.64) | |
Cash per Share |
3.40 | 25.83 | 14.00 | 8.76 | |
Shareholders Equity per Share |
1.71 | 14.99 | 1.36 | (28.93) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.71 | 14.99 | 1.36 | (28.93) | |
Free Cash Flow |
(4.08) | (8.15) | (4.98) | (5.40) | |
Working Capital |
1.78 | 18.49 | 11.37 | 5.24 | |
Capital Expenditures |
— | (0.01) | — | — | |
Net Current Asset Value |
0.95 | (130.08) | (139.16) | (168.06) | |
| Other line items | |||||
Quick Ratio |
1.02 | 5.37 | 2.39 | 1.55 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(4.90) | (11.81) | (5.43) | (5.64) | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Average Receivables |
0.28 | 0.48 | 0.16 | 0.09 | |
Average Payables |
2.55 | 3.10 | 3.90 | 3.12 | |
Average Assets |
4.58 | 84.85 | 85.18 | 79.64 | |
Average Common Equity |
1.54 | 4.16 | 5.77 | (10.77) | |
Capex to Sales |
— | 0.00 | — | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates